DEF 14A

DEF 14A 1 d305005ddef14a.htm DEF 14A DEF 14A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐

Check the appropriate box:


☐		Preliminary Proxy Statement

☐		Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☒		Definitive Proxy Statement

☐		Definitive Additional Materials

☐		Soliciting Material Pursuant to §240.14a-12

AVANTOR, INC.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):



☒		No fee required.

☐		Fee paid previously with preliminary materials.

☐		Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

LOGO

MESSAGE FROM

OUR CHAIRMAN

We are pleased to present our annual proxy statement. In the three years since we completed our IPO, Avantor has been setting science in motion to create a better world. We are a trusted partner to our customers in the life sciences and the advanced technologies and applied materials industries.

Our teams around the globe work hand-in-hand with the world’s leading researchers and scientists to help find comprehensive solutions to some of the most complex challenges in therapy and vaccine development. We keep life-changing science moving forward by supporting our customers in virtually all stages of the most important research, scale-up and manufacturing activities. Avantor is there every step of the way.

In 2021, we closed three acquisitions which collectively increased our capacity to meet growing global demand in bioprocessing, strengthened our offering across all bioproduction platforms, created a differentiated end-to-end fluid management solution a

Table of Contents

Table of Contents

Table of Contents

SEC Form DEF 14A filed by Avantor Inc.